Neuland Laboratories Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Neuland Laboratories Ltd filed with BSE on 16 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Neuland Laboratories reported Q4 FY26 total income of Rs 788.7 crore, up 134.9% year-on-year, driven largely by commercial CMS projects and favorable exchange rates. EBITDA margin for the quarter stood at 40.5%, which management described as exceptional and reflective of record revenue and the uneven nature of the business rather than a sustainable run rate. For the full year, revenue grew 37.1% to Rs 2,053.1 crore with EBITDA margin at 29.4%, while working capital days rose to 137 in Q4FY26 from 107 a year earlier.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Total income: INR788.7 crores (Q4 FY26)
p. 3
“Total income was INR788.7 crores, up 134.9% versus INR335.8 crores in the same period last year.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Gross margin: 62.1% (Q4 FY26)
p. 3
“Gross margin was 62.1% versus 56.3% in Q4FY25, driven largely by the business mix.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
EBITDA: INR319.4 crores, margin of 40.5% (Q4 FY26)
p. 3
“EBITDA stood at INR319.4 crores and a margin of 40.5%.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Profit after tax: INR212.5 crores (Q4 FY26)
p. 3
“Profit after tax was INR212.5 crores versus INR27.7 crores in Q4FY25, and our EPS stands at INR165.6 per share.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Revenue: INR2053.1 crores (FY26)
p. 3
“For the FY, revenue was INR2053.1 crores versus INR1,497.3 crores, a growth of 37.1%.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
EBITDA: INR603.4 crores, margin 29.4% (FY26)
p. 3
“EBITDA was INR603.4 crores versus INR342.8 crores in FY25 with FY26 EBITDA margin at 29.4% compared to 22.9% last year.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Profit after tax: INR363.1 crores, EPS INR283.01 (FY26)
p. 3
“Profit after tax for the full year was INR363.1 crores and EPS stands at INR283.01 per share.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Free cash flow: negative INR49.4 crores (FY26)
p. 4
“For the FY26, the free cash flow was negative at INR49.4 crores, driven primarily by higher working capital during the year, along with increased capital cash outflows.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Capex cash outflow: INR397.1 crores (FY26)
p. 4
“Capex cash outflow for FY26 was INR397.1 crores.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Closing cash balance: INR75.4 crores (FY26)
p. 4
“Closing cash balance of FY26 was INR75.4 crores as compared to INR130.4 crores at the end of the year.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Working capital days: 137 days (Q4 FY26)
p. 4
“Working capital days stood at 137 days in Q4FY26 versus 107 days in Q4FY25, mainly driven by higher inventories and receivables, and we believe that this should normalize in FY27.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Net debt: negative INR157 crores (Q4 FY26)
p. 4
“Net debt remains negative at negative INR157 crores, supported by cash balances of INR353 crores.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Long-term borrowings: INR197 crores (Q4 FY26)
p. 4
“And our long-term borrowings at the end of Q4FY26 was INR197 crores.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Capacity utilization: 85% to 90%; last unit around 65%
p. 11
“So the current capacity utilization of those 3 units are close to between 85% to 90% and the last unit is around 65%.”
Abhijit Majumdar, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Working capital days — normalize · FY27
stated as an aspiration by Abhijit Majumdar
p. 4
“Working capital days stood at 137 days in Q4FY26 versus 107 days in Q4FY25, mainly driven by higher inventories and receivables, and we believe that this should normalize in FY27.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Revenue CAGR — 18% to 20% · over time
stated as an aspiration by Saharsh Davuluri
p. 15
“I think the 18% to 20% CAGR that we talked about is potential that we see.”
Saharsh Davuluri, page 15 of the filed PDF · View the filing
Peptide facility commissioning — operational · July
stated firmly by Saharsh Davuluri
p. 13
“Yes, the facility will be ready by July as per schedule.”
Saharsh Davuluri, page 13 of the filed PDF · View the filing
New commercialization — one commercialization · FY27
stated as an aspiration by Saharsh Davuluri
p. 7
“We're probably looking at one commercialization in FY27 and maybe 1 or 2 more later.”
Saharsh Davuluri, page 7 of the filed PDF · View the filing
ROCE
stated as an aspiration by Saharsh Davuluri
p. 6
“While our ROCE remains healthy, it is expected to moderate as we enter longer capital deployment cycles.”
Saharsh Davuluri, page 6 of the filed PDF · View the filing
Growth outlook — next 2 to 3 years
stated as an aspiration by Saharsh Davuluri
p. 5
“Over the next 2 to 3 years, we have visible growth driven by our existing pipeline.”
Saharsh Davuluri, page 5 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management attributed growth to existing commercial products, ramp-up of volumes, and one new commercialization, not primarily currency.
Answered by Saharsh Davuluri
Asked by Amey Chalke: What is driving the phenomenal CDMO growth beyond currency effects?
p. 7
“Amey, I think we had one new commercialization this year, but we've also had ramp-up of volumes of previously commercialized products.”
Saharsh Davuluri, page 7 of the filed PDF · View the filing
Management said the program is very early-stage and would not associate near or mid-term revenue with it.
Answered by Saharsh Davuluri
Asked by Amey Chalke: What is the revenue timeline for the recently announced peptide contract?
p. 7
“But to be fully transparent with you, it's a very early-stage program, and I would not really associate any near or mid-term revenue coming out of those projects because we do have close to 8 to 10 peptide programs in our development pipeline.”
Saharsh Davuluri, page 7 of the filed PDF · View the filing
Management said they could not comment on specific CDMO molecules but that M&A of sponsor companies is a natural part of the business and usually does not disrupt supply.
Answered by Saharsh Davuluri
Asked by Shyam Srinivasan: How does the Esperion/ArchiMed transaction affect the bempedoic acid business?
p. 10
“I think a lot of biotechs get acquired, some of the biotechs we've contracted with have gotten acquired by big pharma.”
Saharsh Davuluri, page 10 of the filed PDF · View the filing
Management reaffirmed the 18-20% figure as a fair assumption but said margin comparisons should follow the trend line rather than a specific half or quarter.
Answered by Saharsh Davuluri
Asked by Shyam Srinivasan: Should investors rely on the 18-20% CAGR guidance and how should margins be viewed going into FY27/FY28?
p. 11
“I think the 18% to 20% is a fair assumption not necessarily linearly.”
Saharsh Davuluri, page 11 of the filed PDF · View the filing
Management confirmed the facility remains on schedule for July but said contracts are not yet firm since projects are early-stage.
Answered by Saharsh Davuluri
Asked by Ritika: Is the peptide facility on track for July commissioning and are there firm contracts?
p. 13
“I would probably not go as far as to say that we have firm contracts because these are early-stage projects.”
Saharsh Davuluri, page 13 of the filed PDF · View the filing
Management said volatility is inherent as newer high-value molecules enter the mix and does not expect it to disappear.
Answered by Saharsh Davuluri
Asked by Chirag Shah: Is business volatility likely to reduce over time and how much of Q4 was one-off?
p. 13
“So, I don't even necessarily see it as a negative thing. I think as long as we have investor alignment that this volatility is part of our business, I think it's something that we should be okay with.”
Saharsh Davuluri, page 13 of the filed PDF · View the filing
Management declined to characterize the growth as underwhelming or attractive, reiterating the 18-20% CAGR is aspirational over a longer horizon.
Answered by Saharsh Davuluri
Asked by Bharat Shah: Is the roughly 10% compounded growth from FY24 to FY26 underwhelming given the volatility?
p. 15
“And I think the kind of growth we have seen in FY26, where we ended at INR2,000 crores, I think we talked about it on the base of FY24, which was, I think, at about INR1,500-plus crores.”
Saharsh Davuluri, page 15 of the filed PDF · View the filing
Management said the peptide CDMO market opportunity is large and could create another Neuland, but timing and scale remain uncertain.
Answered by Saharsh Davuluri
Asked by Harshit Dhoot: Can the peptide category create another Neuland in terms of numbers over 5+ years?
p. 16
“So, I think the short answer is that it has the potential to create another Neuland for sure.”
Saharsh Davuluri, page 16 of the filed PDF · View the filing
Management said AI use in manufacturing is still at an exploratory, early stage.
Answered by S E Medikonda
Asked by Raghunath: Is Neuland gaining advantages from using AI in manufacturing?
p. 16
“I think there are certain areas in, say, R&D and certain other operations where we have done a few pilots. I think that is where we are at this point of time.”
S E Medikonda, page 16 of the filed PDF · View the filing
Risks flagged
Higher freight costs due to the conflict affecting shipments
p. 3
“We also managed higher freight cost towards the end of the quarter due to the conflict while ensuring continuity of supply to our customers.”
Abhijit Majumdar, page 3 of the filed PDF · View the filing
Raw material coverage and price volatility linked to Middle East developments
p. 4
“Now, given the recent developments in the Middle East, we are closely tracking raw material coverage and price volatility and are taking actions to protect our continuity of supplies and manage the cost pressures.”
Abhijit Majumdar, page 4 of the filed PDF · View the filing
Demand variability, ordering patterns, regulatory timelines, geopolitical developments and supply chain volatility
p. 6
“Our industry continues to be exposed to factors such as demand variability, customer ordering patterns, regulatory time lines, geopolitical developments and supply chain volatility.”
Saharsh Davuluri, page 6 of the filed PDF · View the filing
Uneven revenue realization and variable timing of complex, long-cycle programs
p. 6
“Given the nature of our business, revenue realization can be uneven and the timing of project progression, particularly for complex and long cycle programs can vary.”
Saharsh Davuluri, page 6 of the filed PDF · View the filing
Delays in customer programs or shifts in market dynamics affecting performance and capital productivity
p. 6
“Delays in customer programs, changes in development priorities or shifts in market dynamics can influence both short-term performance and capital productivity.”
Saharsh Davuluri, page 6 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.